BVS857

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Hypercatabolic Status Related to Severe BurnInsulin ResistanceSpinal and Bulbar Muscular Atrophy

Phase 1

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

CompletedNCT01435330

Novartis PharmaceuticalsInsulin Resistance

Start: 2011-03-31End: 2012-03-31Updated: 2015-04-24

Phase 2

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

CompletedNCT02024932

Novartis PharmaceuticalsSpinal and Bulbar Muscular Atrophy

Start: 2014-02-04End: 2016-04-13Updated: 2021-01-05

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

TerminatedNCT02074995

Novartis PharmaceuticalsHypercatabolic Status Related to Severe Burn

Start: 2014-02-28End: 2015-01-31Updated: 2016-03-07

Related Papers

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.

2018-10-1528 citations